文献速递哮喘慢阻肺

NOVELTY研究中可治疗特征的分布与诊断严重度关系

Treatable traits in the NOVELTY study.
PubMed 文献 · Respirology · 2022-07-21

该研究基于NOVELTY全球观察性队列(n=11,226),在真实世界的基层与专科门诊中评估30个常见可治疗特征(TTs)与医生诊断及疾病严重度的关系。结果显示,哮喘、慢阻肺及哮喘合并慢阻肺患者人均TTs分别为4.6±2.6、5.4±2.6和6.4±2.8个(p<0.0001),部分TTs与诊断和严重度相关,但许多并不相关。

要点

  • 哮喘合并慢阻肺患者人均TTs最多(6.4±2.8),高于慢阻肺和哮喘患者。
  • TTs总体地理差异不大,但基层与专科门诊的TTs患病率不同。
  • 部分TTs与诊断和严重度相关,许多TTs并不特异于某一诊断。

核心结论

  • 30个可治疗特征在哮喘、慢阻肺及哮喘合并慢阻肺患者中分布广泛且差异明显,部分与诊断和严重度相关,许多则不相关。
  • 这是迄今真实世界气道疾病患者中规模最大、最细化的TTs特征描述。

研究设计与样本

  • NOVELTY研究为全球多中心观察性纵向研究(NCT02760329),在基层诊所与专科中心系统采集真实世界数据。
  • 共纳入11,226例患者:哮喘5,932例(52.8%)、慢阻肺3,898例(34.7%)、哮喘合并慢阻肺1,396例(12.4%)。
  • 从队列中选取30个常见可治疗特征进行分析。

主要发现

  • 人均TTs数:哮喘4.6±2.6、慢阻肺5.4±2.6、哮喘合并慢阻肺6.4±2.8(p<0.0001)。
  • 30个TTs的患病率差异很大。
  • TTs总体无明显地理差异,但基层与专科门诊的TTs患病率不同。
  • 部分TTs与疾病诊断和严重度相关,许多TTs则无此特异性。
  • TTs的存在与缺失共同形成可被临床医生识别的模式,用于建立诊断和评估严重度。

临床怎么用

  • 提示临床可按TTs模式辅助气道疾病诊断与严重度分级,而非仅依赖诊断标签。
  • 基层与专科门诊TTs分布不同,评估时需结合就诊场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent and complex diseases that require personalized management. Although a strategy based on treatable traits (TTs) has been proposed, the prevalence and relationship of TTs to the diagnostic label and disease severity established by the attending physician in a real-world setting are unknown. We assessed how the presence/absence of specific TTs relate to the diagnosis and severity of 'asthma', 'COPD' or 'asthma + COPD'. METHODS: The authors selected 30 frequently occurring TTs from the NOVELTY study cohort (NOVEL observational longiTudinal studY; NCT02760329), a large (n = 11,226), global study that systematically collects data in a real-world setting, both in primary care clinics and specialized centres, for patients with 'asthma' (n = 5932, 52.8%), 'COPD' (n = 3898, 34.7%) or both ('asthma + COPD'; n = 1396, 12.4%). RESULTS: The results indicate that (1) the prevalence of the 30 TTs evaluated varied widely, with a mean ± SD of 4.6 ± 2.6, 5.4 ± 2.6 and 6.4 ± 2.8 TTs/patient in those with 'asthma', 'COPD' and 'asthma + COPD', respectively (p < 0.0001); (2) there were no large global geographical variations, but the prevalence of TTs was different in primary versus specialized clinics; (3) several TTs were specific to the diagnosis and severity of disease, but many were not; and (4) both the presence and absence of TTs formed a pattern that is recognized by clinicians to establish a diagnosis and grade its severity. CONCLUSION: These results provide the largest and most granular characterization of TTs in patients with airway diseases in a real-world setting to date.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Agustí A, Rapsomaniki E, Beasley R, et al. Treatable traits in the NOVELTY study. Respirology. 2022. PMID: 35861464. doi:10.1111/resp.14325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。